ARCHIVES

DCT Board Committee Drawing Up Plans On How To Spend Biological Response Modifiers Money

This article is from The Cancer Letter archive.

Vol. 05 No. 35 | August 31, 1979

Download PDF Visit The Full Archive

Related Articles

Herceptin Recommended As Adjuvant For HER2 Positive Early Breast Cancer

May 27, 2005

ACS, In Reorganization, To Emphasize Funds for Young Scientists

January 12, 1996

FDA to Move Away From Central Radiology To Investigator Review In PFS Endpoint Trials

July 27, 2012

In Brief: Shingleton Probably Replacement For Marks On Panel; Connie Henke Heads Oncology Nurses

June 8, 1979

December issue of Business & Regulatory Report included (an additional 8 pages of industry news).

December 10, 2004

ODAC Recommends Approval Of Paxen; Will IVAX Break Into $1 Billion Market

September 26, 1997